Welcome to our dedicated page for Icecure Medical Ltd. SEC filings (Ticker: ICCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IceCure Medical Ltd. (Nasdaq: ICCM) is a foreign private issuer that files reports with the U.S. Securities and Exchange Commission (SEC) in connection with its liquid-nitrogen-based cryoablation systems for tumor destruction. On this page, you can review IceCure’s SEC filings, including current reports on Form 6-K that furnish press releases about regulatory milestones, clinical data, commercial progress, and corporate actions.
IceCure’s Form 6-K filings often incorporate press releases by reference into its registration statements on Form F-3 and Form S-8. These filings cover topics such as U.S. Food and Drug Administration (FDA) marketing authorization for the ProSense® Cryoablation System in low-risk breast cancer for women aged 70 and above, regulatory approvals for ProSense® in Switzerland and other markets, notices of patent allowance for technologies like cryogen flow control related to the next-generation XSense™ system, and financial and operational results for specified reporting periods.
Filings also document corporate developments, including changes in management roles and Nasdaq notifications regarding minimum bid price compliance. By reviewing these documents, investors can see how IceCure describes its minimally invasive cryoablation technology, its primary focus areas in breast, kidney, bone, and lung cancer, and the regulatory and commercial steps it reports taking to expand use of ProSense® and XSense™.
Stock Titan’s SEC filings page presents IceCure’s submissions as they are made available on EDGAR and enhances accessibility with AI-powered summaries. These summaries are designed to highlight key points from lengthy documents, such as the nature of a regulatory authorization, the scope of a patent allowance, or the main elements of a financial update. Users can quickly identify filings related to clinical milestones, regulatory approvals, capital markets activity, and other material events disclosed by IceCure Medical Ltd.
IceCure Medical Ltd. executive Tel-Tzure Tlalit Bussi, VP of BD & Global Marketing, reports her initial ownership position. As of March 18, 2026, she beneficially owns 170,629 ordinary shares and restricted share units. She also holds multiple share option grants over ordinary shares at exercise prices ranging from $0.92 to $5.78, with expirations between 2029 and 2034, many of which are fully vested.
IceCure Medical Ltd. Chief Operating Officer Levav Shay filed an initial ownership report showing direct holdings of 144,615 ordinary shares plus several option grants. These options cover 50,000 shares at an exercise price of $1.56, 385 shares at $5.78, 80,668 shares at $3.64, 4,084 shares at $2.84, 40,705 shares at $1.51, and 98,182 shares at $0.92, with expirations ranging from 2030 to 2034. Footnotes state that some grants are already fully vested, while others vest in quarterly installments. In addition, Shay has unvested restricted share units of 81,818, 43,416 and 19,381 units from awards dated July 2, 2024, November 5, 2025 and March 16, 2026, respectively, all unvested as of March 18, 2026.
IceCure Medical Ltd. director Sharon Levita filed an initial insider ownership report on Form 3. The provided data shows no reportable transactions or derivative positions included in this filing.
IceCure Medical Ltd. executive Good Shad, VP Sales for North America, filed an initial statement of ownership showing 156,455 ordinary shares, composed of 6,578 shares and multiple RSU grants that remained unvested as of March 18, 2026. He also holds options to buy 50,000 ordinary shares at $1.22 per share expiring on August 14, 2033, and options on 72,756 ordinary shares at $0.92 per share expiring on July 2, 2034, with portions of each option grant already vested by that date.
IceCure Medical Ltd. Chief Financial Officer Ronen Tsimerman filed an initial Form 3 disclosing his equity holdings in the company. As of March 18, 2026, he holds 16,257 ordinary shares and 161,692 unvested restricted share units that vest over time under two RSU grants.
He also reports multiple share option awards over several years, covering tens of thousands of underlying ordinary shares at exercise prices ranging from $0.79 to $5.78 per share, with expiration dates extending from 2027 through 2034. Many of these options are fully vested, while some continue to vest in quarterly installments.
IceCure Medical Ltd. director Mayron Ron filed an initial Form 3, detailing existing equity holdings rather than new trades. Ron holds 296,631 ordinary shares, consisting of 10,000 shares and 286,631 restricted share units, of which 107,486 have vested and 179,631 remain unvested as of March 18, 2026.
Ron also reports several fully vested share option grants over the company’s ordinary shares: 95,295 options at an exercise price of $1.55 per share expiring in 2028, 25,000 at $1.79 expiring in 2029, 25,000 at $1.68 expiring in 2030, and 110,000 at $3.64 expiring in 2032. An additional 59,295 options at $1.51 per share expiring in 2033 are partly vested, with 44,471 options vested as of March 18, 2026. This filing simply records Ron’s current ownership position.
IceCure Medical Ltd. officer Naum Muchnik, VP of R&D & Engineering, reports his current equity holdings in the company. He holds 118,621 ordinary shares directly, with no buy or sell transactions reported in this filing.
He also holds multiple option grants over ordinary shares, including 4,142 options at an exercise price of $2.27 per share expiring in 2029, 16,000 options at $1.79 expiring in 2029, 27,462 options at $1.56 expiring in 2030, 1,318 options at $5.78 expiring in 2031, 80,668 options at $3.64 expiring in 2032, 4,085 options at $2.84 expiring in 2032, 40,705 options at $1.51 expiring in 2033, and 90,945 options at $0.92 expiring in 2034.
Footnotes state that earlier grants are fully vested as of March 18, 2026, while more recent option and restricted share unit awards vest over time, with portions already vested and the remainder scheduled to vest in equal quarterly installments.
IceCure Medical Ltd. VP of Human Resources Dotan Merav Nir filed a Form 3 disclosing existing equity holdings in the company. The filing shows direct ownership of 68,814 ordinary shares, made up of 500 shares and 68,314 unvested restricted stock units granted in 2024, 2025, and 2026 as of March 18, 2026.
Nir also holds share options over 80,668 ordinary shares at an exercise price of $3.64 per share fully vested and expiring in 2032, 40,705 options at $1.51 expiring in 2033, and 27,283 options at $0.92 expiring in 2034. The Form 3 records these positions only, with no reported purchases or sales.
IceCure Medical Ltd. filed an initial ownership report for Chief Executive Officer Eyal Shamir, detailing his existing equity position. As of March 18, 2026, he directly holds 791,381 ordinary shares, plus a range of vested and unvested equity awards.
Footnotes show additional exposure through restricted share units granted on May 15, 2025; November 5, 2025; and March 16, 2026, with portions vesting in 25% cliffs and 6.25% quarterly installments thereafter. Shamir also holds multiple fully or partially vested share options over ordinary shares with exercise prices converted from Israeli shekels into U.S. dollars, including options over 117,551 shares at an exercise price of $0.82 per share expiring January 23, 2027, and several later grants expiring between 2028 and 2033. The filing records these as holdings only, with no reported recent purchases, sales, or option exercises.
IceCure Medical reported positive 5‑year top-line results from its ICESECRET study of the ProSense® cryoablation system in kidney cancer. At a median follow-up of four years, 83.9% of the 112 evaluated patients with small renal masses were recurrence-free based on imaging.
In a subgroup with tumors ≤3 cm, no prior kidney cancer and successful initial procedures, the recurrence-free rate reached 89.4%. The trial enrolled 114 patients across two centers in Israel, and full data are expected to be presented at the European Conference on Interventional Oncology 2026 in Basel.